Is BioNTech SE (BNTX) Overvalued?
We dive into why BioNTech SE (BNTX) could be considered overvalued on 2026-07-20, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Commentary & Analysis
Which Is a Better Investment, Amgen Inc. or BioNTech SE Stock?
Learn more about whether Amgen Inc. or BioNTech SE is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
What You Need to Know About BioNTech SE's Q2 Earnings
BioNTech SE's fiscal Q2 earnings report was released on Tuesday, May 05. Let's dive in to see if (BNTX) missed or beat analyst's expectations.Tudor Pop
Why BioNTech SE’s (BNTX) Stock Is Down 6.40%
As of Friday, May 01, BioNTech SE’s BNTX share price has dipped by 6.40%, which has investors questioning if this is right time to buy.Michael Rose
Why BioNTech SE’s (BNTX) Stock Is Up 5.50%
As of Tuesday, April 21, BioNTech SE’s BNTX share price has surged by 5.50%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | BNTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $22,906.3 | $252.6 | 87% |
|
| Shares Out (Mil) | 292.0 | 52.3 | 83% |
|
| Institutional Ownership | 55.5% | 92.1% | 37% |
|
| Float (Mil) | 110.1 | 40.2 | 63% |
|
| Beta | 1.37 | 0.95 | 78% |
|
| Avg Daily Volume (000s) | 752 | 455 | 65% |
|
| Price Change (52-week) |
(17.7%) | 52.9% | 32% |
|
| Growth | BNTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 41.7% | 13.6% | 94% |
|
| Net Income (5yr) | (136.3%) | (9.9%) | 1% |
|
| EPS (5yr) | (138.8%) | 16.0% | 0 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (37.7%) | (15.6%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 8 | 7 | |
| Current EPS | ($2.391) | ($4.922) | ($4.979) | |
| Month Ago EPS | ($2.678) | ($5.297) | ($5.091) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($2.638) | ($5.022) | ($4.582) | |
| Year/Year Chg | (1.2%) | (10.8%) | (26.8%) | |
| Financials | BNTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,234 | $38 | 68% |
|
| Net Income (TTM) (Mil) | ($1,444) | ($43) | 1% |
|
| EPS (TTM) | ($5.895) | ($1.600) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | $941 | ($31) | 80% |
|
| Net Cash Flow (TTM) (Mil) | ($372) | $5 | 7% |
|
| Long-Term Debt (Q1) (Mil) | $284 | $5 | 53% |
|
| Enterprise Value (Q1) (Mil) | $7,862 | $180 | 70% |
|
| Valuation | BNTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.06 | 2.56 | 25% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | BNTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 78.7% | 63.8% | 88% |
|
| Net Margin | (44.6%) | (67.3%) | 12% |
|
| ROA | (6.1%) | (49.8%) | 29% |
|
| ROE | (6.9%) | (55.5%) | 30% |
|
| Liabilities to Assets | 11.3% | 30.3% | 7% |
|
| F-Score | 3 | 3 | 19% |
|
BioNTech SE did not pass any screens on 7/31/2026.
